Alzheimer's breakthrough signals game changer for biotech sector

clock • 4 min read
Linden Thomson and Peter Hughes if AXA IM
Image:

Linden Thomson and Peter Hughes if AXA IM

The accelerated approval of the first new Alzheimer's treatment in almost two decades looks set to drive a new wave of biotech innovation and investment.

Alzheimer's disease is a type of dementia that affects memory and other cognitive abilities. Globally, around 50 million people suffer from dementia; there are almost 10 million new cases annually - and...

To continue reading this article...

Join Investment week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

Trustpilot